This content is from: European Union
AstraZeneca faces Losec investigation
The world's biggest selling drug is under attack on both sides of the Atlantic as its patent expiry looms. AstraZeneca, maker of Losec, has been accused of breaching European competition rules, and is also facing litigation to stop US companies bringing out generic versions of the drug.
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here